虫草素降血脂作用及其相关机制的实验研究进展

毕永慧; 李曦; 杨丹凤

PDF(1001 KB)

营养学报 ›› 2025, Vol. 47 ›› Issue (6) : 612-617.

综述

虫草素降血脂作用及其相关机制的实验研究进展

毕永慧^1,2, 李曦², 杨丹凤²

作者信息 +

HYPOLIPIDEMIC EFFECT OF CORDYCEPIN AND UNDERLYING MECHANISMS: PROGRESS IN EXPERIMENTAL STUDIES

BI Yong-hui^1,2, LI Xi², YANG Dan-feng²

Author information +

文章历史 +

摘要

血脂异常作为一种常见的脂代谢紊乱性疾病,与心血管疾病等的发生密切相关。虫草素作为来源于药食同源真菌蛹虫草的一种重要生物活性物质,在调节脂代谢方面展现出良好的潜力,现有实验研究提示其具有降血脂作用。本文综述了虫草素在降血脂方面的实验研究进展,并分析了潜在作用机制,包括抑制脂肪生成、促进脂肪酸氧化、调节肠道菌群-短链脂肪酸轴,以及改善氧化应激、代谢性炎症与自噬稳态等多条途径,以期为虫草素开发及应用提供理论参考。

Abstract

Dyslipidemia is closely associated with the development of cardiovascular diseases. Cordycepin, a key bioactive compound derived from the medicinal fungus Cordyceps militaris, shows promising potential in regulating lipid metabolism. Current experimental evidence indicates its beneficial effects on improving blood lipid profiles. We summarize research progress in the hypolipidemic action of cordycepin based on experimental studies. Its underlying mechanisms are also explored, including inhibition of lipid synthesis, promotion of fatty acid oxidation, modulation of the gut microbiota-short-chain fatty acid axis, and amelioration of oxidative stress, metabolic inflammation, and autophagy homeostasis.

导出引用

毕永慧, 李曦, 杨丹凤. 虫草素降血脂作用及其相关机制的实验研究进展[J]. 营养学报. 2025, 47(6): 612-617

BI Yong-hui, LI Xi, YANG Dan-feng. HYPOLIPIDEMIC EFFECT OF CORDYCEPIN AND UNDERLYING MECHANISMS: PROGRESS IN EXPERIMENTAL STUDIES[J]. Acta Nutrimenta Sinica. 2025, 47(6): 612-617

中图分类号： R151

参考文献

[1] Minic-Novcic M, Park A.Hyperlipidaemia[J]. Medicine, 2025, 53: 702–708.
[2] Li JJ, Zhao SP, Zhao D, et al. 2023 Chinese guideline for lipid management[J]. Front Pharmacol, 2023, 14: 1190934.
[3] Ballena-Caicedo J, Zuzunaga-Montoya FE, Loayza-Castro JA, et al. Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis[J]. J Health Popul Nutr, 2025, 44: 308.
[4] Karalis DG.Editorial commentary: advances in the management of dyslipidemia: The future is bright, but what we do today is what matters most[J]. Trends Cardiovasc Med, 2021, 31: 425–426.
[5] Doshi P, Hong K, Tanveer S, et al. Assessing muscle-related adverse events in randomized trials of statins[J]. J Gen Intern Med, 2022, 37: 3498–3500.
[6] Song DX, Jiang JG.Hypolipidemic components from medicine food homology species used in China: pharmacological and health effects[J]. Arch Med Res, 2017, 48: 569–581.
[7] Ashraf SA, Elkhalifa AEO, Siddiqui AJ, et al. Cordycepin for health and wellbeing: a potent bioactive metabolite of an entomopathogenic cordyceps medicinal fungus and its nutraceutical and therapeutic potential[J]. Molecules, 2020, 25:2735.
[8] Wu X, Wu T, Huang A, et al. New insights into the biosynthesis of typical bioactive components in the traditional Chinese medicinal fungus cordyceps militaris[J]. Front Bioeng Biotechnol, 2021, 9: 801721.
[9] Peng T, Guo J, Tong X.Advances in biosynthesis and metabolic engineering strategies of cordycepin[J].Front Microbiol, 2024, 15: 1386855.
[10] Gong X, Li T, Wan R, et al. Cordycepin attenuates high-fat diet-induced non-alcoholic fatty liver disease via down-regulation of lipid metabolism and inflammatory responses[J]. Int Immunopharmacol, 2021, 91: 107173.
[11] Zhang J, Yang Z, Zhao Z, et al. Structural and pharmacological insights into cordycepin for neoplasms and metabolic disorders[J]. Front Pharmacol, 2024, 15: 1367820.
[12] Heeren J, Scheja L.Metabolic-associated fatty liver disease and lipoprotein metabolism[J]. Mol Metab, 2021, 50: 101238.
[13] Feraco A, Armani A, Gorini S, et al. Gender differences in dietary patterns and eating behaviours in individuals with obesity[J]. Nutrients, 2024, 16:4226.
[14] An Y, Li Y, Wang X, et al. Cordycepin reduces weight through regulating gut microbiota in high-fat diet-induced obese rats[J]. Lipids Health Dis, 2018, 17: 276.
[15] Chen J, Wang M, Zhang P, et al. Cordycepin alleviated metabolic inflammation in Western diet-fed mice by targeting intestinal barrier integrity and intestinal flora[J]. Pharmacol Res, 2022, 178: 106191.
[16] Lee MR, Kim JE, Choi JY, et al. Anti-obesity effect in high-fat-diet-induced obese C57BL/6 mice: study of a novel extract from mulberry (Morus alba) leaves fermented with Cordyceps militaris[J]. Exp Ther Med, 2019, 17: 2185–2193.
[17] Chen M, Luo J, Jiang W, et al. Cordycepin: a review of strategies to improve the bioavailability and efficacy[J]. Phytother Res, 2023, 37: 3839–2858.
[18] Ontawong A, Pengnet S, Thim-Uam A, et al. A randomized controlled clinical trial examining the effects of Cordyceps militaris beverage on the immune response in healthy adults[J]. Sci Rep, 2024, 14: 7994.
[19] Kusama K, Oka K, Yashiro Y, et al. Effect of Cordyceps militaris extract containing cordycepin on the adipogenesis and lipolysis of adipocytes[J]. FEBS Open Biol, 2025, 15: 335–345.
[20] Takahashi S, Tamai M, Nakajima S, et al. Blockade of adipocyte differentiation by cordycepin[J]. Br J Pharmacol, 2012, 167: 561–575.
[21] Guo P, Kai Q, Gao J, et al. Cordycepin prevents hyperlipidemia in hamsters fed a high-fat diet via activation of AMP-activated protein kinase[J]. J Pharmacol Sci, 2010, 113: 395–403.
[22] Tran NKS, Kim GT, Park S H, et al. Fermented cordyceps militaris extract prevents hepatosteatosis and adipocyte hypertrophy in high fat diet-fed mice[J]. Nutrients, 2019, 11:1015.
[23] Foppiani A, Sileo F, Menichetti F,,et al. Predicting glycemic control in patients with impaired fasting glucose with fasting respiratory exchange ratio[J]. J Endocr Soc. Predicting glycemic control in patients with impaired fasting glucose with fasting respiratory exchange ratio[J]. J Endocr Soc, 2025, 9: bvaf047.
[24] Qi G, Zhou Y, Zhang X, et al. Cordycepin promotes browning of white adipose tissue through an AMP-activated protein kinase (AMPK)-dependent pathway[J]. Acta Pharm Sin B, 2019, 9: 135–143.
[25] Petrescu M, Vlaicu SI, Ciumarnean L, et al. Chronic inflammation-a link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue[J]. Medicina (Kaunas), 2022, 58:641.
[26] Raza S, Rajak S, Yen PM, et al. Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD[J]. NPJ Metab Health Dis, 2024, 2: 19.
[27] Han YH, He XM, Jin MH, et al. Lipophagy: a potential therapeutic target for nonalcoholic and alcoholic fatty liver disease[J]. Biochem Biophys Res Commun, 2023, 672: 36–44.
[28] Masenga SK, Kabwe LS, Chakulya M, et al. Mechanisms of oxidative stress in metabolic syndrome[J]. Int J Mol Sci, 2023, 24: 7898.
[29] Li Y, Li Y, Wang XY, et al. Cordycepin modulates body weight by reducing prolactin via an adenosine A1 receptor[J]. J Agric Food Chem, 2022, 70: 14415–14427.
[30] Ahn HY, Cho HD, Cho YS, et al. Anti-oxidant and anti-hyperlipidemic effects of cordycepin-rich Cordyceps militaris in a Sprague-Dawley rat model of alcohol-induced hyperlipidemia and oxidative stress[J]. Bioresour Bioprocess, 2020, 7: 8.
[31] Li J, Zhong L, Zhu H, et al. The protective effect of cordycepin on D-galactosamine / lipopolysaccharide-induced acute liver injury[J]. Mediators Inflamm, 2017, 2017: 3946706.
[32] 缪美琪, 韩宇博, 刘莉.细胞自噬与代谢综合征的相关性及其中医药防治研究进展[J]. 中国现代医学杂志, 2024, 34: 47-53.
[33] Cao T, Xu RP, Xu Y, et al. The protective effect of Cordycepin on diabetic nephropathy through autophagy induction in vivo and in vitro[J]. Int Urol Nephrol, 2019, 51: 1883–1892.
[34] Li T, Wen L, Cheng B.Cordycepin alleviates hepatic lipid accumulation by inducing protective autophagy via PKA/mTOR pathway[J]. Biochem Biophys Res Commun, 2019, 516: 632–638.
[35] Uen WC, Shi YC, Choong CY, et al. Cordycepin suppressed lipid accumulation via regulating AMPK activity and mitochondrial fusion in hepatocytes[J]. J Food Biochem, 2018, 42:e12569.
[36] 梁晨晨, 高建鹏. MSCs通过调控AMPK/mTOR促进自噬改善NASH肝损伤[J]. 昆明医科大学学报, 2023, 44: 162-167.
[37] 陈咪咪, 卢文蕾, 于晏苏,等. 黎药天然产物调控AMPK抗MAFLD作用的研究进展[J]. 海南医学院学报, 2024, 30: 623–633.
[38] Tian HY, Yu DJ, Xie T, et al. Cordycepin alleviates metabolic dysfunction-associated liver disease by restoring mitochondrial homeostasis and reducing oxidative stress via Parkin-mediated mitophagy[J]. Biochem Pharmacol, 2025, 232: 116750.
[39] Li S, Ma X, Mei H, et al. Association between gut microbiota and short-chain fatty acids in children with obesity[J]. Sci Rep, 2025, 15: 483.
[40] Wu J, Wang K, Wang X, et al. The role of the gut microbiome and its metabolites in metabolic diseases[J]. Protein Cell, 2021, 12: 360–373.
[41] Stojanov S, Berlec A, Strukel JB.The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease[J]. Microorganisms, 2020, 8:1715.
[42] Cuciniello R, Di Meo F, Filosa S, et al. The antioxidant effect of dietary bioactives arises from the interplay between the physiology of the host and the gut microbiota: involvement of short-chain fatty acids[J]. Antioxidants (Basel), 2023, 12:1073.
[43] Hu J, Lin S, Zheng B, et al. Short-chain fatty acids in control of energy metabolism[J]. Crit Rev Food Sci Nutr, 2018, 58: 1243–1249.
[44] Prins GH, Rios-Morales M, Gerding A, et al. The effects of butyrate on induced metabolic-associated fatty liver disease in precision-cut liver slices[J]. Nutrients, 2021, 13:4203.
[45] 秦昆鹏, 王志云, 高骞,等. 乙酸对脂肪代谢的影响及其作用机制[J]. 动物营养学报, 2021, 33: 2544-2554.
[46] Roessler J, Zimmermann F, Schumann P, et al. Modulation of the serum metabolome by the short-chain fatty acid propionate: potential implications for its cholesterol-lowering effect[J]. Nutrients, 2024, 16:2368.
[47] Wang G, Sun C, Xie B, et al. Cordyceps guangdongensis lipid-lowering formula alleviates fat and lipid accumulation by modulating gut microbiota and short-chain fatty acids in high-fat diet mice[J]. Front Nutr, 2022, 9: 1038740.
[48] Chen M, Luo J, Jiang W, et al. Cordycepin: a review of strategies to improve the bioavailability and efficacy[J]. Phytother Res, 2023, 37: 3839–3858.